4.3 Review

Corneal Confocal Microscopy: A Biomarker for Diabetic Peripheral Neuropathy

Journal

CLINICAL THERAPEUTICS
Volume 43, Issue 9, Pages 1457-1475

Publisher

ELSEVIER
DOI: 10.1016/j.clinthera.2021.04.003

Keywords

biomarker; clinical trials; corneal con-focal microscopy; diabetic neuropathy

Ask authors/readers for more resources

Corneal confocal microscopy is a rapid, noninvasive method for scanning the living cornea that can serve as an objective, diagnostic biomarker for early diabetic peripheral neuropathy. Research indicates that corneal nerve loss predicts incident neuropathy and progresses with severity, and the microscopy can also identify early corneal nerve regeneration.
Purpose: Diagnosing early diabetic peripheral neu-ropathy remains a challenge due to deficiencies in currently advocated end points. The cornea is densely innervated with small sensory fibers, which are struc-turally and functionally comparable to intraepidermal nerve fibers. Corneal confocal microscopy is a method for rapid, noninvasive scanning of the living cornea with high resolution and magnification. Methods: This narrative review presents the frame-work for the development of biomarkers and the literature on the use and adoption of corneal confocal microscopy as an objective, diagnostic biomarker in experimental and clinical studies of diabetic peripheral neuropathy. A search was performed on PubMed and Google Scholar based on the terms corneal confocal microscopy, diabetic neuropathy, corneal sensitivity, and clinical trials. Findings: A substantial body of evidence underpins the thesis that corneal nerve loss predicts incident neu-ropathy and progresses with the severity of diabetic pe-ripheral neuropathy. Corneal confocal microscopy also identifies early corneal nerve regeneration, strongly arguing for its inclusion as a surrogate end point in clinical trials of disease-modifying therapies. Implications: There are sufficient diagnostic and prospective validation studies to fulfill the US Food and Drug Administration criteria for a biomarker to support the inclusion of corneal confocal microscopy as a primary end point in clinical trials of disease-modifying therapies in diabetic neuropathy. (Clin Ther. 2021;43:1457-1475.) (c) 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available